July 31 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast on Thursday, betting on strong demand for its rare disease drugs such as Skyclarys to offset declining sales of its ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat Wall Street’s expectations.

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 </str ...

Eisai's groundbreaking presentation at the Alzheimer's Association International Conference has revealed a potential game-changer for Alzheimer's treatment that could transform both patient care and ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

Four Years of Lecanemab Therapy Helped Patients Slow the Progression of AD and Remain in the Early Stages of AD Longer Compared to AD’s Natural Course ...

Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Experts don't back specific tests, but provide guidelines on how doctors in specialty care settings can use them to diagnose ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...